dr henny zainal

Welcome

Jumat, 26 Desember 2008

The Medical Home


"Physicians, employers, legislators and payers think medical homes may be the key to health system reform"
Leigh Ann Backer

Physicians have always known the value of a medical home, even when there was no term to describe it. Now, others are recognizing that medical homes may be the key to getting better value from the health care system. In recent months, a wide range of stakeholders including legislators, large employers, patient groups and organized medicine have begun championing medical homes as the centerpiece of a primary-care based approach to health care reform.

The medical home that these plans envision is both old-fashioned and thoroughly modern - a blend of the personalized, comprehensive care that physicians have been offering for decades and coordinated care that capitalizes on new technology and helps patients make sense of the increasingly complex health care system. Whether the concept takes root may depend on two key issues: whether payers can be convinced of the value of medical homes (and the need to pay more for them) and whether physicians can deliver what the medical home promises. This article describes progress in both areas. A future article will offer suggestions for physicians
interested in further developing their practices' medical home characteristics.

What is a medical home?
According to the principles, patient-centered medical homes should have these characteristics: a personal physician, physician-directed medical practice, whole-person orientation, coordinated care, quality and safety, enhanced access and adequate payment.

A fact sheet developed by the organizations paints this picture of the medical home: "In this new model, the traditional doctor's office is transformed into the central point to organize and coordinate their health care, based on their needs and priorities.
At its core is an ongoing partnership between each person and a specially trained primary care physician. This new model provides modern conveniences, like e-mail communication and same-day appointments; quality ratings and pricing information; and secure online tools to help consumers manage their health information, review the latest medical findings and make informed decisions.
Consumers receive reminders about necessary appointments and screenings, as well as other support to help them and their families manage chronic conditions such as diabetes or heart disease. The primary care physician helps each person assemble a team when he or she needs specialists and other health care providers such as nutritionists and physical trainers. The consumer decides who is on his or her team, and the primary care physician makes sure they are working together to meet all of the patient's needs in an integrated, 'whole person' fashion."

With today's payment models, most physicians can't afford to provide the amount of non-face-to- face work required for this type of care, much less the technical infrastructure required to support it. As a result, the linchpin of several developing medical home initiatives is a per-member-per- month care management fee that would be paid in addition to fee-for-service reimbursement. This is seen as a promising development by many physicians, which has advocated for a care management fee for years.

Whether the concept gets implemented the way the Academy hopes it will remains to be seen.
"Financing the changes necessary to provide all the services of a medical home isn't cheap, and I'm not convinced that there's any 'new money' to be had from payers," says Lee Mills, MD, of Newton, Kan.
"Still, structuring care and payment around medical homes is the first reorganizing concept for primary care that has gained traction with payers, the public and the
government. It gets us moving forward, even though it may take a lot of trial and error to develop a formula that serves the interests of all the stakeholders. "

Welcoming the medical home
Medical home demonstration projects and pilot programs have proliferated in the last year, and more are expected:

Medicare has a legislative mandate to implement a medical home demonstration project; the Tax Relief and Health Care Act of 2006 requires that this project commence by 2010. Centers for Medicare & Medicaid Services staff have already begun the work of defining a CPT code for care management that will facilitate payment to medical home practices as called for by the legislation.

Private payers aren't waiting to follow Medicare's lead. In August, United Healthcare announced plans for a medical home pilot project that would pay participating physicians a per-member-per- month care management fee in addition to regular fee-for-service payments for offering medical home services in their practices. The program will be launched in Florida.

CIGNA, Humana, Wellpoint and Aetna have expressed interest in developing their own medical home pilot projects, and the Blue Cross Blue Shield Association has developed a model demonstration project that could be adopted by their member plans. A few Blues plans have developed chronic disease management pilot programs involving care management payments to primary care physicians, and several others have medical home pilot programs in the works.
Large, self-insured employers want to study medical homes as well. IBM is working to develop a medical home initiative that would occur in a community where a large number of IBM employees and their families live. In Washington state, the Boeing Company is implementing a medical home pilot involving high-risk employees who require intense care coordination in primary care practices.

IBM and Boeing are the members of the Patient-Centered Primary Care Collaborative, a coalition representing 50 million workers and 330,000 doctors that advocates for primary-care- based health system reform. The coalition's goals include working to stimulate additional medical home pilots by large, self-insured employers and legislation at the state and federal levels. The group has worked to get medical home language into several bills pending in Congress, according to Kevin Burke.
We have invested $8 million in TransforMED, a national demonstration project launched in June 2006 that is focused on helping participating practices implement a new model of care that includes medical home components.

A growing number of state governments are interested in incorporating medical homes into the health care programs they fund. Seventy-seven bills have been introduced in 21 states and the District of Columbia, according to Greg Martin, state policy analyst. "These bills run the gamut from a mere passing use of the term 'medical home' to bills creating medical home demonstration projects or systems of care," Martin says.

Many states would like to follow in the footsteps of Community Care of North Carolina (CCNC), a program in which physician-led networks offer medical homes to Medicaid enrollees. CCNC pays each network $3 per Medicaid patient per month, and each physician receives an additional $2.50 per month for each of his or her Medicaid patients. The program was launched in 1998 with nine pilot networks covering 250,000 enrollees and has since been rolled out across the state. CCNC saved the state $60 million in Medicaid costs in 2003 and $120 million in 2004, according to one analysis.

Of course cost is only half of the value equation, and proponents of the medical home concept expect to demonstrate improved quality as well. Several studies have established that having a regular source of care and continuous care with the same physician over time leads to better health outcomes as well as lower costs, and medical homes are designed to provide this type of care. A recent survey by the Commonwealth Fund concluded that adults who have medical homes have enhanced access to care and receive better quality care. The survey defined medical homes as regular health care providers that offer timely, well-organized care and enhanced access.

NCQA patient-centered medical home designation program
To qualify as a medical home under the NCQA program, practices would need to meet at least five of the 10 "priority criteria":

. Has written standards for patient access and patient communication;
. Uses data to show it meets its standards for patient access and communication;
. Uses paper or electronic charting tools to organize clinical information;
. Uses data to identify important diagnoses and conditions in practice;
. Implements evidence-based guidelines for at least three conditions;
. Actively supports patient self-management;
. Tracks tests and identifies abnormal results systematically;
. Tracks referrals using a paper-based or electronic system;
. Measures clinical or service performance by physician or across the practice;
. Reports performance by physician or across the practice.

Practices would also need to select and meet additional criteria from a longer list, still under development. Each criterion would be associated with specific processes, and at least half of the processes would need to be in place. A yet-to-be-determine d application fee and documentation that the practice meets the criteria would also be required. Practices could pay a small fee for access to an online self-assessment module before submitting a formal application.

How do we get there from here?
As interest in medical homes has grown, so have definitions of what it means to provide one. "It's a diffuse concept, and it will help to develop a single definition that all the stakeholders can operationalize, " Mills says.

To this end, the primary care societies have been working with the National Committee for Quality Assurance (NCQA) to reach consensus on a set of measures that would provide a uniform way of implementing the concept of the medical home, according to Phyllis Torda, vice president of product development for NCQA. The Board of Directors recently voted to support pilot testing of an NCQA program titled Physician Practice Connections-Patient-Centered Medical Home, which will use the agreed-upon measures to qualify practices as medical homes. United Healthcare intends to use the program in its medical home pilot, according to John Swanson.

"Fair and consistent assessment of whether practices qualify as medical homes is critical, and it's reasonable to expect that payers will require that an independent organization do this work," Mills says, although he has mixed feelings about giving up control of the process and the data to an outside organization. "It may be a necessary evil."

Karen Smith, MD, of Raeford, N.C., recently reviewed the proposed NCQA criteria in detail. She is confident that her rural solo practice would qualify as a medical home, although not at the highest level without some additional work. "We really embraced the Future of Medicine recommendations when they came out several years ago, including adopting an electronic health record system, so we're performing or are capable of performing many of the medical home functions," Smith says.

Her practice has also been participating in the Community Care of North Carolina program for several years, and she believes the program's care management fee (described above) has helped her to improve her practice's quality and efficiency. "It has provided us with an incentive, but it's not enough to finance big changes," she says.

The care management fee will be pivotal in a practice's ability to function as the kind of medical home that payers want, Mills says. "The amount should be more than enough to simply cover the associated costs."

Mills and Smith are confident that many practices could qualify as medical homes, although research suggests that relatively few now have the characteristics associated with medical homes. According to the 2006 Practice Profile Survey, the most commonly offered medical home components are chronic disease management (47 percent of practices), electronic health records (41 percent), Web-based information for patients (38 percent) and open-access scheduling (31 percent). Rates of adoption are lower for other services:
. 25 percent use a team approach to care.
. 24 percent use registries or patient tracking systems.
. 22 percent use e-mail to communicate with patients.
. 22 percent use e-prescribing.
. 13 percent use clinical practice guidelines software.
. 13 percent do outcomes analyses.
. 12 percent use Web-based consults or e-visits.

In addition to needing an adequate care management fee, practices will need education to help them redesign their systems of care to meet medical home criteria, Smith says. Learnings from the TransforMED demonstration project and CME opportunities focused on medical homes will be instrumental in enabling practices to achieve these goals. "I'm very optimistic that with this help, an incentive, and a better understanding among patients and other providers of the value that a medical home provides, we can redesign our practices in a way that will serve everyone well," she says.

The medical home concept centers on characteristics that drew many physicians to the specialty, including the opportunity to provide patient-centered, coordinated, comprehensive care to patients of all ages over time in the context of their family and their community. However, the pressures of managed care have made this vision harder to achieve. Only time will tell whether the medical home movement will bring these values, and the value of medicine, back into focus. [AAFP]

Kamis, 25 Desember 2008

Penyebab Kematian Telah Bergeser Dari Penyakit Menular

Penyebab kematian di Indonesia untuk semua umur, telah terjadi pergeseran dari penyakit menular ke penyakit tidak menular. Penyebab kematian perinatal (0-7 hari) yang terbanyak adalah respiratory disorders (gagguan pernafasan) (35,9%) dan premature (32,3%), sedangkan untuk usia (7-28 hari) penyebab kematian yang terbanyak adalah sepsis neonatorum (infeksi bakteri) (20,5%) dan congenital malformations (kelainan pada janin) (18,1%). Penyebab kematian bayi yang terbanyak adalah diare (31,4%) dan pneumonia (23,8%). Sedangkan untuk penyebab kematian anak balita sama dengan bayi, yaitu terbanyak adalah diare (25,2%) dan pneumonia (15,5%). Sedangkan untuk usia > 5 tahun, penyebab kematian yang terbanyak adalah stroke, baik di perkotaan maupun di pedesaan.

Hal itu disampaikan dr. Triono Sundoro, Ph.D, Kepala Badan Penelitian dan Pengembangan Kesehatan (Balitbangkes) Depkes pada Simposium Nasional IV hasil Riset Kesehatan Dasar (Riskesdas) tanggal 2 Desember 2008 di Jakarta.

Riskesdas menghasilkan berbagai data penting masalah kesehatan, misalnya prevalensi gizi buruk yang berada diatas rata-rata nasional (5,4%) ditemukan pada 21 provinsi dan 216 kabupaten/kota. Sedangkan berdasarkan gabungan hasil pengukuran Gizi Buruk dan Gizi Kurang Riskesdas 2007 menunjukkan bahwa sebanyak 19 provinsi mempunyai prevalensi Gizi Buruk dan Gizi Kurang diatas prevalensi nasional sebesar 18,4%. Namun demikian, target Rencana Pembangunan Jangka Menengah untuk pencapaian program perbaikan gizi yang diproyeksikan sebesar 20%, dan target Mil/enium Development Goals sebesar 18,5% pada 2015, telah dapat dicapai pada 2007, tutur dr. Triono.

Menurut dr. Triono, Posyandu merupakan tempat yang paling banyak dikunjungi untuk penimbangan balita yaitu sebesar 78,3%; balita yang ditimbang secara rutin (4 kali atau lebih), ditimbang 1-3 kali dan yang tidak pernah ditimbang) berturut-turut adalah 45,4%, 29,1%, dan 25,5%. Sedangkan kegiatan di posyandu untuk pemberian suplemen gizi (47,6%), PMT (45,7%), pengobatan (41,2%) dan imunisasi (55,8%). Secara keseluruhan, cakupan imunisasi pada anak usia 12 - 23 bulan menurut jenisnya yang tertinggi sampai terendah adalah untuk BCG (86,9%), campak (81,6%), polio tiga kali (71,0%), DPT tiga kali (67,7%) dan terendah hepatitis B (62,8%), ujar dr. Triono.

Sedangkan proporsi bayi berat lahir rendah (BBLR) sebesar 11,5% (berdasarkan catatan yang ada), dan ibu hamil yang memeriksaan kehamilan sebanyak 84,5%. Pemeriksaan yang paling sering dilakukan pada ibu hamil adalah pemeriksaan tekanan darah (97.1%) dan penimbangan berat badan ibu (94,8%). Sedangkan jenis pemeriksaan kehamilan yang jarang dilakukan pada ibu hamil, adalah pemeriksaan hemoglobin (33,8%) dan pemeriksaan urine (36,4%), kata dr. Triono.

Khusus untuk provinsi Nusa Tenggara Timur, Maluku, Maluku Utara, Papua Barat dan Papua ditemukan sebanyak 60% melahirkan bayinya di rumah. Penolong persalinan yang dominan di perkotaan adalah bidan [61,7%), sedangkan di perdesaan yang dominan adalah dukun bersalin (45,9%).

Hasil utama Riskesdas 2007 menggambarkan hubungan penyakit degeneratif seperti sindroma metabolik, stroke, hipertensi, obese dan penyakit jantung dengan status sosial ekonomi masyarakat (pendidikan, kemiskinan, dll). Penyakit hipertensi misalnya, tidak berkaitan dengan tingkat sosial ekonomi (kuintil pengeluaran/distribusi penduduk berdasarkan tingkat pengeluaran per kapita) seperti pada kuintil 1 (30,5%) dan kuintil 5 (33,0%), dan mulai banyak dijumpai pada kelompok usia muda 15-17 tahun (8,3%).

Tidak ada perbedaan perilaku merokok antara status sosial ekonomi rendah dan tinggi. Ditemukan peningkatan proporsi usia mulai merokok pada umur <20 tahun, dari 10,3% (SKRT, 2001) menjadi 11,9% (Riskesdas, 2007), tutur dr. Triono.

Proporsi low vision (penglihatan terbatas) di Indonesia adalah sebesar 4,8% (Asia 5% - 9%), kebutaan 0,9% dan katarak (1,8%) yang meningkat dari 1,2% menurut SKRT 2001. Patut diduga bahwa peningkatan jumlah kasus katarak ini berkaitan erat dengan peningkatan umur harapan hidup penduduk Indonesia pada periode 2005-2010 (69,1 tahun) dibanding periode 2000-2005 (66,2 tahun). Prevalensi nasional gangguan mental emosional pada penduduk yang berumur ~ 15 tahun adalah 11,6%, ujar dr. Triono.

Mengenai pentingnya Riskesdas, dr. Triono menyatakan, hingga kini belum tersedia data berbasis populasi yang memadai untuk perencanaan pembangunan sampai tingkat kabupaten/kota. Untuk itu, Balitbangkes Depkes menyelenggarakan Riskesdas 2007. Riskesdas adalah kegiatan riset yang diarahkan untuk mengetahui gambaran kesehatan dasar penduduk termasuk biomedis yang dilaksanakan dengan cara survey rumah tangga di seluruh wilayah kabupaten/kota secara serentak dan periodik.

Dalam Riskesdas 2007 berhasil dikumpulkan sebanyak 258.366 sampel rumah tangga dan 987.205 sampel anggota rumah tangga untuk pengukuran berbagai variabel kesehatan masyarakat. Riskesdas 2007 juga mengumpulkan 36.357 sampel untuk pengukuran berbagai variabel biomedik dari anggota rumah tangga yang berumur lebih dari 1 tahun yang bertempat tinggal di desa/kelurahan dengan klasifikasi perkotaan.

Khusus untuk pengukuran gula darah, berhasil dikumpulkan sebanyak 19.114 sampel yang diambil dari anggota rumah tangga berusia lebih dari 15 tahun. Untuk tes cepat yodium, berhasil dilakukan pengukuran pada 257.065 sampel rumah tangga. Sedangkan untuk pengukuran yodium di dalam urin, berhasil dilakukan pengukuran pada 8.473 sampel anak berumur 6-12 tahun yang tinggal di 30 kabupaten/kota dengan berbagai kategori tingkat konsumsi yodium, ujar dr. Triono.

Riskesdas, lanjut dr. Triono, merupakan salah satu perwujudan 4 grand strategy Depkes, yaitu berfungsinya sistem informasi kesehatan yang evidence-based melalui pengumpulan data dasar dan indikator kesehatan. Indikator yang dihasilkan antara lain meliputi status kesehatan dan faktor penentu kesehatan yang bertumpu pada konsep Henrik Blum, merepresentasikan gambaran wilayah nasional, provinsi dan kabupaten/kota.

Menurut dr. Triono, pertanyaan yang menjadi dasar pengembangan Riskesdas 2007 adalah: 1. Bagaimana status kesehatan dan faktor penentu kesehatan, baik di tingkat nasional, provinsi dan kabupaten/kota; 2. Bagaimana hubungan antara kemiskinan dan kesehatan; dan 3. Apakah terdapat masalah kesehatan yang spesifik?

Untuk menjawab ketiga pertanyaan tersebut, ujar dr. Triono, dirumuskan tujuan antara lain penyediaan data dasar status kesehatan dan faktor penentu kesehatan, baik di tingkat rumah tangga maupun tingkat individual, dengan ruang lingkup : 1. Status gizi; 2. Akses dan pemanfaatan pelayanan kesehatan; 3. Sanitasi lingkungan; 4. Konsumsi makanan; 5. Penyakit menular, penyakit tidak menular dan riwayat penyakit keturunan; 6. Ketanggapan pelayanan kesehatan; 7. Pengetahuan, sikap dan perilaku; 8. Disabilitas; 9. Kesehatan mental; 10. Imunisasi dan pemantauan pertumbuhan; 11. Kesehatan bayi; 12. Pengukuran anthropometri, tekanan darah, /ingkar perut dan lingkar lengan atas; 13. Pengukuran biomedis; 14. Pemeriksaan visus; 15. Pemeriksaan gigi; 16. Berbagai autopsiverbal peristiwa kematian; dan 17. Mortalitas.

Dr. Triono menyatakan, disain Riskesdas 2007 merupakan survei cross sectional yang bersifat deskriptif. Populasi dalam Riskesdas 2007 adalah seluruh rumah tangga di seluruh pelosok Republik Indonesia. Sam- pel rumah tangga dan anggota rumah tangga dalam Riskesdas 2007 dirancang identik dengan daftar sampel rumah tangga dan anggota rumah tangga Susenas 2007. Berbagai ukuran sampling error termasuk didalamnya standard error, relative standard error, confidence interval, design effect dan jumlah sampel tertimbang menyertai setiap estimasi variabel.

Dr. Triono mengakui adanya keterbatasan Riskesdas, mencakup non-random error antara lain: pembentukan kabupaten baru, blok sensus tidak terjangkau, rumah tangga tidak dijumpai, periode waktu pengumpulan data yang berbeda, estimasi tingkat kabupaten tidak bisa berlaku untuk semua indikator, dan data biomedis yang hanya mewakili blok sensus perkotaan. Khusus untuk lima provinsi (Papua, Papua Barat, Maluku, Maluku Utara dan NTT) baru dilaksanakan pada bulan Agustus-September 2008, sementara 28 provinsi lainnya telah selesai dilaksanakan pada tahun 2007.

Menurut dr. Triono, hasil Riskesdas ini sangat bermanfaat sebagai asupan dalam pengembangan kebijakan dan perencanaan program kesehatan. Dengan 900 variabel, maka hasil Riskesdas 2007 telah dan dapat digunakan antara lain untuk pengembangan riset dan analisis lanjut, pengembangan nilai standar baru berbagai indikator kesehatan, . penelusuran hubungan kausal-efek, dan pemodelan statistik.

Berita ini disiarkan oleh Pusat Komunikasi Publik Setjen Depkes RI. Untuk informasi lebih lanjut dapat menghubungi telp./fax. 52907416-19 /529-21669, 5223002 atau email puskom. publik@yahoo.co.id.

Rabu, 24 Desember 2008

ASAS KEDOKTERAN ISLAM

Pada dasarnya ilmu kedokteran sifatnya umum dan berlaku secara universal. Akan tetapi di dalamnya ada yang Islami, yaitu yang sejalan dengan syara’ atau yang tidak berlawanan dengannya. Ada pula yang tidak Islami, yaitu yang tidak sejalan dengan syara’ atau berlawanan dengannya.

ASAS KEDOKTERAN ISLAM

Ath-Thibb-Ul- Islam-I atau kedokteran Islam tiada lain adalah ilmu pengobatan yang berasaskan Islam dengan prinsip-prinsip pengobatan, antara lain :

Pertama, mengobati pasien dengan ihsan,dan tidak melakukan hal-hal yang bertentangan dengan Al Quran dan Sunnah Nabi-Nya.

Kedua, tidak sekali-kali menggunakan obat- obatan yang haram atau tercampuri bahan yang haram. Umpamanya menggunakan arak, opium, delfaa, hasyisy, dan darah, sebagai obat, atau mencampur obat dengan bahan yang haram seperti membuat sirup obat berlarutan bahan al-Ghul(alkohol) , membuat pil berbahan campur opium dan sejenisnya yang melenakan tetapi mempengaruhi akal, yaitu khamar basah dan khamar kering.

Firman Allah SWT dan beberapa hadist Rasulullah SAW tentang larangan menggunakan khamar,antara lain : “Mereka ada bertanya kepadamu dalam perkara khamar dan judi,
maka katakanlah bahwa keduanya itu dosa besar tetapi ada kemanfaatan bagi manusia tetapi dosanya lebih besar daripada manfaatnya itu.” (QS.Al Baqarah,2:219)

Dari Wa’il al-Hadlrami, sesungguhnya telah bertanya Thariq bin Suwaid kepada Rasulullah SAW tentang khamar yang ia jadikan obat. Maka sabda Nabi SAW,”Itu
bukanlah obat melainkan penyakit.” (HR.Muslim dan Abu Dawud)

Sabda Nabi SAW,”Sesungguhnya Allah tidak menjadikan kesembuhan dengan sesuatu yang Ia haramkan atasmu.” (HR.al-Bukhariy)

Sabda Nabi SAW,”Semua yang memabukkan itu khamar dan semua khamar itu haram.” (HR. Muslim)

Sabda Nabi SAW,”Minuman apapun jika kadar banyaknya memabukkan, sedikitnya pun haram.” (HR. at-Tirmidziy)

Adapun mabuk khamar itu musykir penuh khayal, pengubah akal tapi bukan mabuk seperti makan racun, sabda Nabi SAW,”Sesungguhnya khamar itu pengubah akal.”

Banyak ramuan obat yang dibuat oleh ahli farmasi bangsa Eropa menggunakan pepsina babi. Sedangkan di antara obat-obatan ramuan China, ada yang berkandungan darah, sumsum babi, dan serbuk tulang mayat manusia. Hal tersebut jelas keharamannya, firman
Allah SWT : “Haram atasmu bangkai, darah, daging babi dan binatang yang disembelih dengan nama Allah; binatang yang mati tercekik atau terpukul, atau karena jatuh, atau karena ditanduk binatang lain dan yang dimakan binatang buas,kecuali jika kamu sembelih binatang itu. Dilarang juga makan binatang yang disembelih atas nama berhala dan meramal nasib baik dan buruk dengan undian anak panah. Yang demikian
itu fasiklah…” (QS. Al-Maidah,5: 3)

Ketiga, pengobatan itu tidak sekali- sekali mencacatkan tubuh, kecuali jika keadaannya sangat darurat dan tidak ada pengobatan lain di saat itu, seperti menggunakan al-kayy bakar ketika digigit ular di tengah sahara.

Rasulullah SAW bersabda : “Sesungguhnya obat itu ada pada tiga perkara yaitu minum madu, berbekam dan berkayy dengan api, maka terlaranglah bagi umatku ber-kayy dengan api itu.” (HR.al-Bukhariy)

Syekh Abdurrahman al-Harani pernah berkata dalam bukunya Thibb al-Islami: “Dalam perkara berobat dengan pengobatan yang mencacatkan itu terdapat darurat atasnya dan dalam obat berbahan haram , tiada darurat atasnya karena Allah SWT tidak menurunkan obat dari barang yang haram.” (Thibb-ul-Islami, Hal.406)

Keempat, pengobatan itu tidak berbau takhyul, khurafat, dan bid’ah. Sesungguhnya Islam tidak mengajarkan berobat dengan air wafaq, azimat yang berbau syirik seperti kita dapatkan dalam kitab-kitab kain berjubah Islam atau mengatasnamakan Islam. Islam
tidak mengajarkan mantera-mantera dan sihir.

Rasulullah SAW bersabda : “Semua tangkal penangkal, jampi selampik itu syirik.”(HR.Ahmad)
Adalah Nabi SAW menyuruh berobat tetapi melarang keras berobat pada seorang kahin(dukun) , maka sabdanya : “Siapa pun yang datang kepada seorang dukun menanyakan suatu perkara lalu membenarkan ucapan dukun itu, kufurlah ia terhadap apa yang diturunkan kepada Muhammad, dan barang siapa datang sambil tidak membenarkannya, tiada diterima shalatnya selama empat puluh hari.”(HR.ath-Thabrani)

Kelima, Islam tidak membenarkan seseorang yang tidak mengkaji ilmu kedokteran turun mengobati pasien, sehingga jika terjadi bahaya, ia harus bertanggungjawab
sepenuhnya.

Maka sabda Nabi SAW: “Jika suatu perkara diserahkan bukan pada ahlinya, tunggulah
kehancurannya.” (HR.al-Bukhariy)

“Barang siapa bertindak sebagai tabib, sedang ia sebelumnya belum pernah mengkaji ilmu ath-thibb (kedokteran) , maka ia harus mengganti kerugian.” (HR.Abu Dawud, Nasaiy, dan Ibnu Majah)
“Seseorang yang bertindak sebagai tabib merawat orang-orang sakit,sedangkan ia
tidak mengetahui sebelumnya cara perawatan medis, sehingga menyebabkan si pasien lebih parah, maka ia harus bertanggungjawab.” (HR.AbuDawud)

Keenam, jauhkanlah bagi seorang tabibmuslim itu iri hati, riya, takabur, merendahkan orang lain, tinggi hati,memeras pasien, dan sifat tidak terpuji lainnya.

Sabda Nabi SAW : “Sesungguhnya sesuatu yang kutakutkan itu syirik kecil yaitu riya.” (HR.Ahmad)

“Sesungguhnya Allah SWT telah mewajibkan kepadaku; hendaklah kamu merendahkan hati agar seseorang tidak melewati batas seseorang dan seseorang tidak bersombong akan seseorang.” (HR.Muslim)

“Celakalah sudah penyembah dinar dan dirham dan qathifah, jika diberi ia ridha dan jika tidak ia tidak ridha.” (HR.al-Bukhariy)

“Sesungguhnya Nabi SAW telah berbekam dan membayar kepada pembekam itu, lalu
beliau memasukkan obat ke dalam hidung.” (HR.Muslim)

Ketujuh, seorang tabib Muslim itu harus berpakaian rapi, bersih dan sebaiknya berpakaian putih. Allah SWT berfirman : “Dan pakaianmu hendaklah kamu bersihkan dan maksiat hendaklah kamu jauhi.” (QS.Al-Muddatstsir, 74:4-5)

“Sesungguhnya Allah menyukai orang-orang yang bertaubat serta menyukai orang- orang
yang bersih.” (QS Al-Baqarah,2: 222)

“Sesungguhnya Allah itu bersih dan menyukai kebersihan, maka bersihkanlah halaman-halamanmu.” (HR. at-tirmidzi)

“Rapikanlah pakianmu, dan hiasilah kendaranmu, sehingga kamu terpandang di dalam pergaulan.” (HR.al-Hakim)

Menurutpepatah,”Pemurah hati itu pertanda kebersihan hati..” Rasulullah SAW bersabda :“Pemurah hati itu hampir kepada Allah, kepada surga dan kepada manusia.” (HR.at-Tirmidziy)

“Pakailah pakaian putih, karena sesungguhnya waran putih itu lebih bersih dan indah, kafanilah mayat-mayatmu dengan kain putih.” (HR.Ahmad)

Kedelapan, hendaklah pula lembaga kedokteran, rumah sakit, balai pengobatan dan semacamnya menarik hati pengunjung, indah, rapih dan bersih sehingga menjadi tempat penyiaran Islam.

Kesembilan, jauhkanlah lambang-lambang dan
istilah-istilah yang berasal dari pemujaan pada dewa-dewa (jahiliah) ataupun penggunaan lambang keagamaan dari orang-orang Yahudi dan Nasrani,walaupun
istilah-istilah itu sudah merata, sudah diakui dan sudah dilatahkan oleh tabib-tabib Muslim pengikut mereka, yang menjadi muqallid mereka.

Dalam hal ini dapat diambil contoh Henri Dunant (1828-1910), seorang dokter berkebangsaan Swiss. Ia seorang penginjil yang gigih menyebarkan agamanya melalui lembaga sosial dan merupakan salah seorang penggagas konvensi Jenewa pada
tahun 1862. Ia dianugerahi hadial Nobel pada tahun 1901 atas jasa-jasanya meletakkan dasar organisasi sedunia untuk menolong korban peperangan yang mayoritas
adalah anak-anak, perempuan, serta orang-orang melarat. Kebanyakan korban tersebut menderita luka-luka, kelaparan, dan penderitaan lainnya. Maka ditetapkanlah di Jenewa organisasi sedunia yang dibangun Henri Dunant tersebut dengan lambang “Palang
Merah” yang diambil dari Salib Suci Katolik, yang awalnya berarti:”Kasih Yesus tidak mengenal perbedaan bangsa.”(W.D.Velikoretsky: Histori of Medicine ,79)

Mengenai hal ini Rasulullah SAW bersabda : “Barang siapapun yang meniru suatu kaum, maka ia termasuk kaum itu.” (HR.Ahmad & Abu Dawud)

Dari Aisyah.r.a:”Sesungguhnya Rasulullah SAW tidaklah membiarkan di rumahnya sesuatu pun yang menyerupai salib-salib, melainkan diubahnya dan dibatalkannya.”(HR.al-Bukhariy)

Syekh‘Utsman Kurki dalam Kitab Syarah Thibb-un-Nabiy; 396 berkata : “Adalah Nabi
SAW sangat membenci semua upacara atau semua istilah atau semua lambang yang berasal dari adat agama jahiliah atau Ahli Kitab, yahudi dan nasrani yang telah merusak wasiat Nabinya dan telah mengambil agama lain sebagai penghias bid’ahnya itu.”

Sesungguhnya praktek kedokteran pada zaman Nabi SAW yang dilakukan sendiri oleh beliau adalah mengatur makan dan minum, shaum, minum madu, minum air putih,
susumurni, kurma dan semacamnya. Nabi SAW pun berolahraga dan berobat, diantaranyadengan berbekam.

Pada masa Nabi SAW pun berkembang pengobatan ramuan, fashid,dan al-kayy bakar. Ahli al-kayy yang terkenal dari sahabat Nabi SAW adalah AbiThalhah. Namun, Nabi SAW kurang menyukai al-kayy bakar karena menyebabkan cacatyang adakalanya sampai seumur hidup.

(oleh : dr. Mahesa Paranadipa. Kutipan dari Buku Kedokteran Islam:Sejarah& Perkembangannya, DR.Ja’far Khadem Yamani)

Jumat, 29 Februari 2008

Penumbra Aspiration Device Safe, Effective for Recanalization in Stroke

February 28, 2008 (New Orleans, Louisiana) — Results of a prospective, single-cohort, phase 2 study show safety and effectiveness for recanalization of the Penumbra System aspiration catheter in patients with acute stroke due to large vessel occlusion.
Results were presented here at the American Stroke Association International Stroke Conference 2008. The study was funded by Penumbra Inc, maker of the system, and designed by the company in collaboration with the Food and Drug Administration (FDA) to support an approval application; FDA approval for the aspiration device was received by the company in January 2008, when it was judged to be "substantially equivalent" to another currently approved mechanical device, the Concentric Balloon Guide Catheter (Concentric Medical Inc) for the indication of revascularization of patients with acute ischemic stroke secondary to large vessel occlusive disease within 8 hours of symptom onset.
"The device was able to achieve a higher-than-usual rate of recanalization (82%) with a low complication rate, with a range of intracerebral hemorrhages seen after stroke that are compatible with previous studies," said Cameron MacDougall, MD, chief of endovascular surgery at Barrow Neurological Institute, in Phoenix, Arizona, who presented the results here.
Phase 2 Study
The Penumbra System comprises a series of devices, primarily an aspiration catheter, with a distal wire to keep the catheter clear, and a grasping device designed to remove harder thrombus if the aspiration device fails to recanalize the vessel, Dr. MacDougall said.
In this phase 2 trial, 125 patients from 24 international centers with acute large vessel stroke were enrolled if they had failed treatment with intravenous tissue plasminogen activator (tPA) or were not candidates for treatment. Main entry criteria were an National Institutes of Health Stroke Scale (NIHSS) score of 8 or higher, presentation within 8 hours of symptom onset, and an occlusion (TIMI 0 or 1) of a treatable intracranial vessel.
Primary end points were revascularization of the target vessel, defined as TIMI 2 or 3 flow, and the incidence of procedural serious adverse events. Angiographic results were adjudicated by an independent core laboratory.
Mean age of the cohort was 64 years, with a baseline NIHSS score of 17.6 (range, 8 to 34), and a baseline modified Rankin Scale (mRS) of 4.5.
Revascularization of the target vessel was achieved in 82% of patients, all using the aspiration device only, Dr. MacDougall said. In fact, the grasping device was not approved because it was not effectively tested in enough patients in this study, he said.
There were 4 serious adverse events that were deemed to be procedure-related, but not device-related. Of these, 2 events occurred in the same patient; after failure of recanalization with the aspiration device, the investigator followed up with an angioplasty balloon that resulted in a perforation of the vessel and a subarachnoid hemorrhage and a parenchymal hemorrhage.
A third event, a parenchymal hemorrhage, occurred immediately after recanalization and was deemed a reperfusion hemorrhage that again was procedure- but not device-related. The fourth event was a small subarachnoid hemorrhage without hematoma that was felt to be a wire perforation, Dr. MacDougall said.
At 24 hours, intracranial hemorrhage (ICH) was seen in 35 patients (28%), 14 (11.2%) defined by computed tomography (CT) evidence of a bleed and deterioration of 4 points or more on the NIHSS. All-cause mortality was 26.4% at 30 days and 32.8% at 90 days.
Although the trial was not powered to look at clinical outcomes, the researchers reported that a favorable outcome at 30 days, defined as a 4-point improvement on the NIHSS at discharge or a 30-day mRS of 2 or less, was seen in 41.6% of patients. At 90 days, 25% of patients had an mRS of 2 or less. "The trend for a better outcome when vessels were opened was consistently seen across all neurological and functional measures," the authors write.
It is of note that Dr. MacDougall, while he presented the results here, was not the principal investigator for this trial; the trial actually did not have a principal investigator, a situation that he agreed was "odd."
"This was a company-sponsored, company-designed trial, in which the local principal investigators, including myself, did not control the design," he said. Instead, the design was defined through meetings of the company with the FDA, and end points were set comparing outcomes with the original Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial of the Merci retriever device.
Does Recanalization Equal Better Outcomes?
The approval of another device for revascularization of large vessels on the basis of recanalization in a single-cohort trial, rather than on improved clinical outcomes in controlled clinical trials, again raises the controversial issue of disparate approval processes by the FDA for drugs vs devices in the setting of stroke treatment.
Devices must be shown to be safe and to be effective in what they purport to do — in this setting, recanalizing the stroke-related vessel. Drug approval generally requires 2 studies showing safety and efficacy in phase 3 trials, comparing the drug with a control and looking at hard clinical outcomes.
"This is a prospective, phase 2 single-arm trial, so that's the beginning and end of the story," said Larry Goldstein, MD, from Duke University Medical Center, in Durham, North Carolina, who has written at length on this issue and was not involved in this trial. "The device can apparently remove clots. Whether that leads to better patient outcomes is not proven by this study," he told Medscape Neurology & Neurosurgery.
Although it would seem intuitive that an open vessel is better than a closed one, to date none of the approved devices have been shown in a randomized trial to actually improve outcomes. In the field of cardiology, for example, studies have begun to suggest that late revascularization of established clots may provide no ultimate benefit to the patient. At least 2 ongoing studies have incorporated mechanical clot removal in their trial design — the Interventional Management of Stroke Trial III (IMS III), and the Magnetic Resonance and Recanalization of Stroke Clots Using Embolectomy (MR-RESCUE). .
At a press conference here, Dr. MacDougall agreed there is an imperative for these types of devices, and this device in particular, to be tested in a randomized controlled trial powered to look at clinical outcomes. "That's what we care about, that the outcomes are better. Whether it's through the IMS III or some other mechanism, I think it's very important to get this into randomized trials where we can demonstrate that."
Although his involvement in the development of the Penumbra System is limited to this trial, he noted, "It's my understanding that plans are under way to move toward a mechanism for a randomized trial."
In the meantime, however, session moderator and American Stroke Association program committee chair Philip Gorelick, MD, from the University of Illinois College of Medicine, in Chicago, emphasized the importance of informed consent on this issue.
"Right now, it's exceedingly important that those who are potentially deploying the device have this very frank discussion with family and patients — if they are competent at the time of the stroke — so that they understand there is safety, that stroke is a bad disease that could lead to mortality, and there are potential risks here of using the device. But in terms of definitively showing [whether] the hard stroke outcomes in terms of stroke severity and poststroke function down the road will be improved, we don't really know."
The study was designed and funded by Penumbra Inc. Dr. MacDougall reports no financial disclosure relevant to this presentation.
American Stroke Association International Stroke Conference 2008: Abstract LB 4. Presented February 22, 2008.

Makanan dan Susu Formula Bayi yang beredar di Indonesia Terkontaminasi Enterobacter sakazakii

Peneliti Fakultas Kedokteran Hewan Institut Pertanian Bogor (IPB) yang terdiri dari Dr. Sri Estuningsih, mengungkapkan sebanyak 22,73 persen susu formula (dari 22 sampel) dan 40 persen makanan bayi (dari 15 sampel) yang dipasarkan antara April - Juni 2006 telah terkontaminasi Enterobacter sakazakii. " Sampel makanan dan susu formula yang kami teliti berasal dari produk lokal," kata Estu. Menurut Estu, selain dirinya, beberapa staf pengajar Fakultas Kedokteran Hewan IPB yang bergabung dalam penelitian ini antara lain: Drh.Hernomoadi Huminto MVS, Dr. I.Wayan T. Wibawan, dan Dr. Rochman Naim.
Penelitian ini dilakukan melalui dua tahap. Tahap pertama, isolasi dan identifikasi E.sakazakii dalam 22 sampel susu formula dan 15 sampel makanan bayi. Tahap kedua, menguji 12 isolat E.sakazakii dari hasil isolasi dan kemampuannya menghasilkan enteroksin (racun) melalui uji sitolisis (penghancuran sel). Dari 12 isolat yang diujikan terdapat 6 isolat yang menghasilkan enteroksin. Uji selanjutnya adalah menguji isolat tersebut pada kemampuan toksinnya setelah dipanaskan. Terdapat 5 dari 6 isolat tersebut yang masih memiliki kemampuan sitolisis setelah dipanaskan.
Selanjutnya Estu menentukan satu kandidat dari isolat tersebut dan menguji enterotoksin serta bakteri vegetatifnya pada bayi mencit berusia enam hari. Bayi mencit diinfeksi melalui rute oral (cekok mulut) menggunakan sonde lambung khusus dan steril. Setelah 3 hari kemudian dilakukan pengambilan sampel organ mencit tersebut. "Hasil pengujian enteroksin murni dan enteroksin yang dipanaskan dan bakteri mengakibatkan enteritis (peradangan saluran pencernaan), sepsis (infeksi peredaran darah) dan meningitis (infeksi pada lapisan urat saraf tulang belakang dan otak). Pemeriksaan tersebut dilakukan dengan metode hispatologi menggunakan pewarnaan Hematoksilin Eosin.
Penelitian ini menyimpulkan di Indonesia terdapat susu formula dan makanan bayi yang terkontaminasi oleh E. Sakazakii yang menghasilkan enterotoksin tahan panas dan menyebabkan enteritis, sepsis dan meningitis pada bayi mencit. Dari hasil pengamatan histopatologis yang diperoleh masih dibutuhkan penelitian senada yang lebih mendalam untuk mendukung hasil penelitian tersebut. Sangat penting dipahami bahwa susu formula bayi bukanlah produk steril, sehingga dalam penggunaannya serta penyimpanannya perlu perhatian khusus untuk menghindari kejadian infeksi karena mengkonsumsi produk tersebut.
Estu secara pribadi telah menlihat langsung fasilitas salah satu perusahaan makanan dan susu formula dengan omzet terbesar di Indonesia. "Sebagian besar fasilitas tersebut telah memenuhi standar operasional prosedure perusahaan susu formula bayi, dan saat ini masih terus dilakukan upaya untuk mencegah kontaminasi tersebut," ujar Estu. (ris)

Strategies for Diagnosis and Treatment of Impetigo

April 3, 2007 — Diagnosis and treatment strategies for impetigo are reviewed in the March 15 issue of American Family Physician.

"Impetigo is a highly contagious infection of the superficial epidermis that most often affects children two to five years of age, although it can occur in any age group," write Charles Cole, MD, and John Gazewood, MD, MSPH, from the University of Virginia School of Medicine in Charlottesville. "Among children, impetigo is the most common bacterial skin infection and the third most common skin disease overall, behind dermatitis and viral warts. Impetigo is more common in children receiving dialysis."

The authors searched Ovid Evidence-Based Medicine, the National Guideline Clearinghouse, the TRIP database, Clinical Evidence, and MEDLINE (1996 - 2005) and reviewed appropriate articles about impetigo.
There are 2 types of impetigo: nonbullous impetigo (impetigo contagiosa) and bullous impetigo. The former represents a host response to the infection, whereas the latter is caused by staphylococcal toxin, and no host response is required to manifest clinical illness.

Staphylococcus aureus is the most important causative organism; Streptococcus pyogenes (group A β-hemolytic streptococcus) causes fewer cases, either alone or combined with S aureus.

The diagnosis of impetigo usually is made clinically, but confirmation with Gram stain and culture may be helpful on occasion. Culture may help identify patients with nephritogenic strains of S pyogenes during outbreaks of poststreptococcal glomerulonephritis, or methicillin-resistant S aureus in suspected cases.

Nonbullous impetigo starts as a single red macule or papule that rapidly becomes a vesicle that ruptures easily to form an erosion. The vesicle contents dry to form characteristic honey-colored, often pruritic crusts. Autoinoculation often causes spread to surrounding areas. Nonbullous impetigo often affects the extremities, face, or other areas subject to trauma. If the infection is not treated, it usually resolves spontaneously without scarring in several weeks.

Impetiginous or secondary impetigo is a subtype of nonbullous impetigo that can complicate systemic diseases, such as diabetes mellitus and AIDS.
Bullous impetigo occurs most frequently in neonates but also can occur in older children and adults. This form of impetigo is a localized form of staphylococcal scalded skin syndrome caused by toxin-producing S aureus. Superficial vesicles rapidly develop into enlarging, flaccid bullae with sharp margins and no surrounding erythema. Yellow crusts with oozing occur when the bullae rupture. The "collarette" of scale surrounding the blister roof at the periphery of ruptured lesions is pathognomonic.

This form of impetigo typically develops at moist, intertriginous areas, such as the diaper area, axillae, and neck folds. Systemic symptoms are infrequent but can include weakness, fever, and diarrhea. Cases are usually sporadic and self limited, resolving in a few weeks without scarring.

Impetigo usually heals spontaneously within 2 weeks without scarring. However, treatment helps alleviate discomfort, improves cosmetic appearance, and prevents the spread of an organism linked to other illnesses, such as glomerulonephritis. In 5 placebo-controlled randomized trials, 7-day cure rates ranged from 0% to 42%.

Adults may have a higher risk for complications than children. Incidence of acute poststreptococcal glomerulonephritis is between 1% and 5% of patients with nonbullous impetigo, and the risk for this serious complication is not affected by treatment with antibiotics. Other rare potential complications include sepsis, osteomyelitis, arthritis, endocarditis, pneumonia, cellulitis, lymphangitis or lymphadenitis, guttate psoriasis, toxic shock syndrome, and staphylococcal scalded skin syndrome.
Despite the lack of standard treatment of impetigo, many options are available. The topical antibiotics mupirocin and fusidic acid are effective and may be superior to oral antibiotics, but the latter should be considered for patients with extensive disease. Topical disinfectants are not helpful to treat impetigo.

Although oral penicillin V is seldom effective, there is otherwise no clear preference among antistaphylococcal penicillins, amoxicillin/clavulanate, cephalosporins, and macrolides. However, resistance rates to erythromycin are rising.
Specific recommendations are as follows:
• For impetigo involving limited body surface area, topical antibiotics such as mupirocin and fusidic acid (not available in the United States) are the preferred first-line therapy (level of evidence, A).

• Oral antibiotics that are effective for treatment of impetigo are antistaphylococcal penicillins, amoxicillin/clavulanate, cephalosporins, and macrolides. Erythromycin is less effective (level of evidence, A).

• For patients with more extensive impetigo or disease associated with systemic symptoms, oral antibiotics should be considered (level of evidence, C).

• Oral penicillin V, amoxicillin, topical bacitracin, and neomycin are not recommended for the treatment of impetigo (level of evidence, B).

• Topical disinfectants such as hydrogen peroxide should not be used in the treatment of impetigo (level of evidence, B).

"Treatments ideally should be effective, inexpensive, and have limited side effects," the authors conclude. "Topical antibiotics have the advantage of being applied only where needed, which minimizes systemic side effects. However, some topical antibiotics may cause skin sensitization in susceptible persons."

Clinical Context
Impetigo, a highly contagious infection of the superficial epidermis, typically affects children aged 2 to 5 years, but it can affect people of all ages. It is the most common bacterial skin infection in children and the third most common skin disease overall. Nonbullous impetigo (impetigo contagiosa) represents a host response to the infection, whereas bullous impetigo is caused by staphylococcal toxin. S aureus is the most important causative organism; S pyogenes (group A β-hemolytic streptococcus) is responsible for fewer cases.

Impetigo is usually diagnosed clinically and can be confirmed by Gram stain and culture, but this is seldom necessary. Although impetigo usually heals spontaneously within 2 weeks without scarring, treatment helps to relieve discomfort, improve cosmetic appearance, and prevent the spread of staphylococcal infections. Despite the lack of standard treatment of impetigo, many options are available and effective.

Study Highlights
• The reviewers searched Ovid Evidence-Based Medicine, the National Guideline Clearinghouse, the TRIP database, Clinical Evidence, and MEDLINE (1996 - 2005) for articles about impetigo.

• Impetigo is usually transmitted through direct contact and often spreads rapidly through schools and daycare centers. After excoriating an infected area, patients can further spread the infection to themselves or others, and fomites also are important in the spread of impetigo. The incidence is greatest in the summer months, especially in crowded living conditions or in areas with poor hygiene.

• In 1 UK study, annual incidence of impetigo was 2.8% in children 4 years or younger and 1.6% among children 5 to 15 years of age.

• Impetigo is usually diagnosed clinically and is occasionally confirmed with Gram stain and culture, which can help identify patients with nephritogenic strains of S pyogenes or methicillin-resistant S aureus.

• In nonbullous impetigo, a red macule or papule on the extremities, face, or other areas subject to trauma rapidly becomes a vesicle that ruptures to form an erosion. The vesicle contents dry to form characteristic honey-colored, often pruritic crusts.

• Impetiginous (secondary) impetigo is a type of nonbullous impetigo associated with systemic diseases, such as diabetes mellitus and AIDS. Insect bites, varicella, herpes simplex virus, and other conditions disrupting skin integrity predispose patients to common impetigo.

• In bullous impetigo, superficial vesicles at moist, intertriginous areas rapidly develop into enlarging, flaccid bullae with sharp margins and no surrounding erythema. Yellow crusts with oozing occur when the bullae rupture. The "collarette" of scale surrounding the blister roof at the periphery of ruptured lesions is pathognomonic. This form of impetigo, which is seen most often in neonates but also can occur in older children and adults, is a localized form of staphylococcal scalded skin syndrome caused by toxin-producing S aureus.

• For impetigo involving limited body surface area, topical antibiotics such as mupirocin and fusidic acid (not available in the United States) are effective and are the preferred first-line therapy. Topical antibiotics are applied only where needed, thereby minimizing systemic adverse effects, but they may cause skin sensitization in susceptible persons.

• Topical disinfectants are not helpful to treat impetigo, and topical bacitracin and neomycin are not recommended.

• For patients with more extensive impetigo or disease associated with systemic symptoms, oral antibiotics should be considered. Although oral penicillin V or amoxicillin are seldom effective, there is otherwise no clear preference among antistaphylococcal penicillins, amoxicillin/clavulanate, cephalosporins, and macrolides. However, resistance rates to erythromycin are rising, thus making it less effective.

• Without treatment, most cases of impetigo resolve spontaneously in 2 weeks without treatment. In 5 placebo-controlled randomized trials, 7-day cure rates ranged from 0% to 42%.

• Adults may have a higher risk for complications than children. Incidence of acute poststreptococcal glomerulonephritis is between 1% and 5% of patients with nonbullous impetigo, and the risk for this serious complication is not affected by treatment with antibiotics. Other rare potential complications include sepsis, osteomyelitis, arthritis, endocarditis, pneumonia, cellulitis, lymphangitis or lymphadenitis, guttate psoriasis, toxic shock syndrome, and staphylococcal scalded skin syndrome.